



## The ANDROMEDA-SHOCK TRIAL

Guest: Dr. Rory Spiegel

Assistant Professor of Emergency Medicine, Department of Emergency Medicine

Critical Care Fellow, Department of Medicine

University of Maryland School of Medicine, Baltimore, MD

### **Key Article**

*Hernandez G, et al. Effect of a resuscitation strategy targeting peripheral perfusion status vs serum lactate levels on 28-day mortality among patients with septic shock. The ANDROMEDA-SHOCK randomized clinical trial. JAMA. 2019; epub ahead of print.*

### **Study Background**

- Early resuscitation a key factor to limit progression to MODS and death in patients with septic shock
- Shock is characterized by increased serum lactate levels and signs of tissue hypoperfusion including abnormal peripheral perfusion
- SSC proposes to guide hemodynamic resuscitation by repeated measurement of lactate every 2 to 4 hours until normalization
- Hyperlactatemia may be related to causes other than tissue hypoperfusion, lactate kinetics is relatively slow, and measurements of lactate levels may not be universally available
- Observational studies shown that persistent abnormal peripheral perfusion after resuscitation is associated with organ failure and mortality
- Capillary refill time - easy-to-use resource-independent method to assess peripheral perfusion; rapidly responds to resuscitation

### **Study Objective**

- Compare a peripheral perfusion targeted resuscitation to lactate level targeted resuscitation in patients with early septic shock

### **Study**

- Multicenter, randomized clinical trial
- 28 hospitals in 5 countries (Argentina, Chile, Colombia, Ecuador, Uruguay)
- Patients
  - Consecutive adult patients ( $\geq 18$  years of age)
  - Septic shock (defined as suspected or confirmed infection plus lactate  $\geq 2$  mmol/L and requirements of vasopressors to maintain MAP  $\geq 65$  mm Hg after an IVF bolus of at least 20 ml/kg over 60 minutes)

- Admitted to an ICU
  - Recruited within 4 hours after fulfilling criteria
- Excluded bleeding, severe ARDS, and DNR
- Randomly allocated to a peripheral perfusion-targeted resuscitation or a lactate level-targeted resuscitation
- Interventions
  - Period was 8 hours
  - CRT
    - Measured by applying firm pressure to the ventral surface of the R index finger distal phalanx was a glass microscope slide
    - Pressure increased until skin was blank and maintained for 10 seconds
    - Time to normal skin color recorded with a chronometer
    - CRT > 3 seconds abnormal
  - Lactate assessed every 2 hours; CRT assessed every 30 minutes; until normalization and then every hour during the intervention period
  - Goal CRT - normalize CRT
  - Goal lactate - normalize or decrease levels by 20% every 2 hours
  - First step
    - Assess fluid responsiveness - each center used its standard technique - followed by fluid challenges with 500 ml of crystalloids every 30 min in responders until goal was achieved
    - In patient who could not be assessed for responsiveness, fluids were continued until the goal was met or safety limit reached
  - Second step
    - In patients with chronic hypertension, if the previous interventions did not meet the goals, a vasopressor test was conducted, transiently increasing norepi until reaching a MAP of 80-85 mm Hg, followed by reassessment of CRT or lactate after 1 to 2 hours
    - If goal was met, the MAP was maintained throughout the intervention period
    - If not, norepi dose was decreased to previous dose and moved to next step
  - Third step
    - Inodilator test
    - Low dose dobutamine or milrinone if target was not reached
    - CRT and lactate reassessed every 1 to 2 hours
    - If end points were not met or a safety issue arose, the inodilator was discontinued
- Primary Outcome - all-cause 28-day mortality
- Secondary Outcomes
  - Death in 90 days
  - Organ dysfunction during the first 72 hours
  - Mechanical ventilation free days within 28 days
  - Vasopressor free days within 28 days

- ICU and hospital LOS
- Tertiary Prespecified exploratory outcomes
  - Resuscitation fluids during the intervention period
  - Total fluid balance within 8, 24, and 72 hours
  - Occurrence of IAH within 72 hours
  - RRT within 28 days
  - In-hospital mortality
- Statistical Analysis
  - Plan to enroll 420 patients to detect a reduction in 28-day mortality from 45% to 30%

## Results

- 424 patients were enrolled
  - 212 assigned to each group
  - All patients included in the ITT analysis for primary outcome
  - Baseline characteristics similar
  - 71% admitted from the ED; 17% from wards, 7% from step-down units, 5% from OR
- Adherence to protocol
  - 13.7% of patients in the peripheral perfusion group
  - 10.8% in the lactate group
  - Most were protocol deviations and 8 patients did not receive the assigned intervention
- Resuscitation, Perfusion, and Hemodynamic Variables
  - Fluid responsiveness
    - 57% were fluid responsive at baseline
    - 25% fluid unresponsive at baseline
    - 18% could not be determined
    - PPV and PLR with VTI most common methods used
  - Fewer patients in the CRT group required a vasopressor test (28.8% vs. 40.1%)
  - 15.6% of patients received a inodilator test
  - Lactate levels significantly lower at 48 and 72 hours in the CRT group (mean difference -0.36); no statistical difference at 2, 4, 8, and 24 hours
  - CRT values significantly lower at 4, 8, and 24 hours in the CRT group (-0.45 seconds), with no statistical difference at 2, 48, and 72 hours
- Primary Outcome
  - CRT: 34.9%
  - Lactate: 43.4%
  - HR 0.75, CI 0.55-1.02; p=0.06
- Secondary Outcomes
  - Less organ dysfunction at 72 hours in the CRT group (SOFA -1.00)
  - No differences in the other 6 outcomes
- Tertiary

- Patients in the CRT group received less fluids within the first 8 hours (-408 ml; CI -705 to -110)

### **Limitations**

- Non-blinded
- Study may have been underpowered to exclude a clinically meaningful difference between groups
- Inter-rater variability for CRT was not evaluated
- Randomization not stratified by sites
- ICU-based study

### **Author's Take Home Point**

- A resuscitation strategy targeting normalization of CRT compared with lactate did not reduce all-cause 28-day mortality